Compare SEVN & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEVN | ALXO |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9M | 172.8M |
| IPO Year | 2008 | 2020 |
| Metric | SEVN | ALXO |
|---|---|---|
| Price | $6.70 | $1.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $8.70 | $4.60 |
| AVG Volume (30 Days) | 175.7K | ★ 1.4M |
| Earning Date | 10-27-2026 | 11-24-2026 |
| Dividend Yield | ★ 16.72% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $15.13 | N/A |
| Revenue Next Year | $16.21 | N/A |
| P/E Ratio | $13.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $0.86 |
| 52 Week High | $9.81 | $2.66 |
| Indicator | SEVN | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 44.49 |
| Support Level | $5.98 | $1.03 |
| Resistance Level | $7.05 | $1.34 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 64.21 | 29.49 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.